Chronic Pain | Pharmacor | G7 | 2015
Despite the extensive armamentarium of chronic pain therapies—and the fact that the market is increasingly subject to generics competition—the chronic pain market continues to represent a notable commercial opportunity for drug developers. Indeed, developers continue to pursue development of products with novel mechanisms of action as well as products with the potential to fulfill the lingering unmet need for safer and better tolerated analgesics. Recently launched and emerging abuse-deterrent opioid analgesic reformulations, as well as novel products such as biologic drugs targeting nerve growth factor, are expected to greatly impact the overall dynamics of the chronic pain market across the major pharmaceutical markets we cover. The increasing prevalence of key population segments, including osteoarthritis pain and chronic low back pain, will be an additional key driver of growth over the forecast period.
